Comprehensive Germline Mutation Analysis for Inherited Cancer Risk
The IDNGS™ Genetic Hereditary Cancer Panel is an advanced Next-Generation Sequencing (NGS) assay designed to identify inherited mutations associated with a wide spectrum of cancers. This panel provides targeted analysis of genes implicated in hereditary cancer syndromes, enabling early detection, personalized risk assessment, and improved clinical decision-making for patients and their families.
By analyzing key germline mutations, the panel supports diagnosis, surveillance, and preventive strategies in individuals with a family history of cancer or suspected genetic predisposition.
Covers 30+ high and moderate-risk genes including BRCA1, BRCA2, TP53, MLH1, MSH2, PALB2, APC, and others
Detects Single Nucleotide Variants (SNVs), Insertions/Deletions (indels), and splice-site mutations
Compatible with whole blood, saliva, or buccal swab samples
Clinical-grade data interpretation based on ACMG/AMP guidelines
Rapid turnaround time with high analytical sensitivity and specificity
Developed under ISO 13485 and suitable for clinical IVD use
| Parameter | Details |
|---|---|
| Panel Name | IDNGS™ Genetic Hereditary Cancer Panel |
| Genes Covered | 30+ (BRCA1, BRCA2, TP53, MLH1, MSH2, PALB2, APC, etc.) |
| Technology | Targeted Next-Generation Sequencing (NGS) |
| Sample Type | Whole Blood, Saliva, Buccal Swab |
| DNA Input | ≥10 ng |
| Variants Detected | SNVs, Indels, Splice-site mutations |
| Intended Use | Germline mutation detection for inherited cancer syndromes |
| Clinical Applications | Breast, Ovarian, Colorectal, Prostate, Endometrial, Pancreatic Cancers |
| Turnaround Time | 10–14 working days |
| Regulatory Compliance | ISO 13485, ACMG/AMP, IVD-compatible |
Copyright © 2025 https://probgenbiotech.com/ All Rights Reserved.